Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 26, 2026Journal for ImmunoTherapy of CancerOpen Access

Aging is associated with the outcomes of immune checkpoint blockade in renal cell carcinoma

View Full Paper
Ask AI
Bookmark
Share

Authors

ZHZhiyang HuangFujian Medical UniversityJZJie ZhouZhejiang Chinese Medical UniversityZZZhengrong Zheng

Discussion

Loading...

Member takes

Implication

Pooled analysis reveals aging affects outcomes of immunotherapy in renal cell carcinoma, indicating individualized treatment is essential.

Key Points

  • To investigate how aging influences immunotherapy outcomes in advanced renal cell carcinoma patients.
  • Pooled analysis of individual participant data from two randomized controlled trials: CheckMate 214 and JAVELIN Renal 101.
  • Population includes 1926 participants: 964 treated with immune checkpoint inhibitors and 962 with sunitinib.
  • Age cut-off for analysis defined at 60 years old.
  • Immunotherapy associated with favorable overall survival (OS) in young patients (HR=0.70, 95% CI 0.56 to 0.87, p<0.001).
  • Marginal OS benefits noted in patients over 60 years (HR=0.82, 95% CI 0.67 to 1.00, p=0.05).
  • No OS improvement for patients aged 75 and above (HR=1.05, 95% CI 0.62 to 1.79, p=0.85).

Cite This Study

Huang et al. (2026) studied this question.

synapsesocial.com/papers/69edac074a46254e215b3dcahttps://doi.org/10.1136/jitc-2025-014605
View Full Paper
Ask AI
Bookmark
Share